Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis
Abstract
Patient non-compliance is the major drawback associated with the long-duration chemotherapy of tuberculosis (TB); hence, reduction in dosing frequency forms an important therapeutic strategy. The present study reports the formulation of three frontline antitubercular drugs (ATD), i.e. rifampicin (RIF), isoniazid (INH) and pyrazinamide (PZA) encapsulated in poly (DL-lactide-co-glycolide) (PLG) nanoparticles. Drug encapsulation efficiencies were 56.9+/-2.7% for RIF, 66.3+/-5.8% for INH and 68+/-5.6% for PZA. Following a single oral administration of these preparations to mice, the drugs could be detected in the circulation for 6 days (RIF) and 9 days (INH/PZA), whereas therapeutic concentrations in the tissues were maintained for 9-11 days. Further, on oral administration of drug-loaded nanoparticles to Mycobacterium tuberculosis-infected mice at every 10th day, no tubercle bacilli could be detected in the tissues after 5 oral doses of treatment. Therefore, nanoparticle-based ATD therapy forms a sound basis for reduction in dosing frequency for better management of TB.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Polymer-based nanoparticles (PLGA and sodium alginate) have been developed to improve the oral bioavailability of rifampicin, isoniazid, ethambutol, pyrazinamide and streptomycin.
“Polymer-based nanoparticles (PLGA and sodium alginate) have also been developed to improve the oral bioavailability of rifampicin, isoniazid, ethambutol, pyrazinamide and streptomycin 124-127 .”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [126]
Cites
Biodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617 · see citing works
Biologically erodable microspheres as potential oral drug delivery systems
Mathiowitz, E., Jacob, J. S., Jong, Y. S., Carino, G. P., Chickering, D. E., Chaturvedi, P., Santos, C. A., Vijayaraghavan, K., Montgomery, S., Bassett, M., et al. (1997) · Nature · doi:10.1038/386410a0 · Cited by 823 · see citing works
Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration
Jacobs, C., & Müller, R. H. (2002) · Pharmaceutical Research · doi:10.1023/a:1014276917363 · Cited by 439 · see citing works
Truncated hemoglobin HbN protects Mycobacterium bovis from nitric oxide
Ouellet, H., Ouellet, Y. H., Richard, C., Labarre, M., Wittenberg, B. A., Wittenberg, J. B., & Guertin, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092017799 · Cited by 267 · see citing works
Defining the drug incorporation properties of PLA–PEG nanoparticles
Govender, T. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00375-6 · Cited by 225 · see citing works
In Vitro and In Vivo Evaluation of Oral Heparin–Loaded Polymeric Nanoparticles in Rabbits
Jiao, Y., Ubrich, N., Marchand-Arvier, M., Vigneron, C., Hoffman, M., Lecompte, T., & Maincent, P. (2002) · Circulation · doi:10.1161/hc0202.101988 · Cited by 200 · see citing works
Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification
Lamprecht, A., Ubrich, N., Pérez, M. H., Lehr, C., Hoffman, M., & Maincent, P. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00107-6 · Cited by 169 · see citing works
Deol, P., & Khuller, G. K. (1997) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(96)00088-8 · Cited by 160 · see citing works
Self-citationInvestigation of polymeric nanoparticles as carriers of enalaprilat for oral administration
Grabnar, P. A., Kristl, J., Kristl, A., & Vrečer, F. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00076-5 · Cited by 157 · see citing works
Horisawa, E., Hirota, T., Kawazoe, S., et al. (2002) · Pharmaceutical Research · doi:10.1023/a:1015123024113 · Cited by 135 · see citing works
Dutt, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.6.829 · Cited by 88 · see citing works
Kılınç, O., Uçan, E. S., CAKAN, M. D. A., et al. (2002) · Respiratory Medicine · doi:10.1053/rmed.2002.1315 · Cited by 54 · see citing works
Saito, H., & Tomioka, H. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.4.429 · Cited by 50 · see citing works
Dutt, M., & Khuller, G. K. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.363-366.2001 · Cited by 48 · see citing works
Self-citationFluorometric determination of isonicotinic acid hydrazide in serum.
Scott, E. M., & Wright, R. C. (1967) · PubMed · Cited by 48 · see citing works
Quenelle, D. C., Winchester, G. A., Staas, J. K., Barrow, E. L. W., & Barrow, W. W. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1637-1644.2001 · Cited by 44 · see citing works
Ain, Q. U., Sharma, S., Garg, S. K., & Khuller, G. K. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00034-0 · Cited by 37 · see citing works
Self-citationGrandfils, C., Flandroy, P., & Jérôme, R. (1996) · Journal of Controlled Release · doi:10.1016/0168-3659(95)00102-6 · Cited by 37 · see citing works
Atovaquone and rifabutine-loaded nanocapsules: formulation studies
Dalençon, F., Amjaud, Y., Lafforgue, C., et al. (1997) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00076-8 · Cited by 35 · see citing works
Lopes, E., Pohlmann, A. R., Bassani, V. L., et al. (2000) · PubMed · Cited by 35 · see citing works
Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids.
Gurumurthy, P., Nair, N., & Sarma, G. R. (1980) · PubMed · Cited by 18 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Nanotechnology approaches for global infectious diseases
Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520 · see citing works
Nanotechnology in agro-food: From field to plate
Dasgupta, N., Ranjan, S., Mundekkad, D., Ramalingam, C., Shanker, R., & Kumar, A. (2015) · Food Research International · doi:10.1016/j.foodres.2015.01.005 · Cited by 437 · see citing works
Pandey, R., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2004.11.003 · Cited by 318 · see citing works
Self-citationInhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis
Zahoor, A., Sharma, S., & Khuller, G. K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.07.012 · Cited by 314 · see citing works
Self-citationOral solid lipid nanoparticle-based antitubercular chemotherapy
Pandey, R., Sharma, S., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2005.08.009 · Cited by 271 · see citing works
Self-citationPharmaceutical nanotechnology: from the bench to the market
Mazayen, Z. M., Ghoneim, A. M., Elbatanony, R. S., Basalious, E. B., & Bendas, E. R. (2022) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-022-00400-0 · Cited by 208 · see citing works
Pulmonary drug delivery systems for tuberculosis treatment
Pham, D.-D., Fattal, E., & Tsapis, N. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.12.009 · Cited by 185 · see citing works
Sharma, A., Pandey, R., Sharma, S., & Khuller, G. K. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.07.010 · Cited by 111 · see citing works
Self-citationNanoparticle-Based Oral Drug Delivery System for an Injectable Antibiotic – Streptomycin
Pandey, R., & Khuller, G. K. (2007) · Chemotherapy · doi:10.1159/000110009 · Cited by 80 · see citing works
Self-citationTiny Things with Enormous Impact: Nanotechnology in the Fight Against Infectious Disease
Mitchell, S. L., & Carlson, E. E. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00138 · Cited by 23 · see citing works
- Authors
- Pandey, R., Zahoor, A., Sharma, S., & Khuller, G. K.
- Affiliations
- Post Graduate Institute of Medical Education and Research (IN)
- Corresponding author
- Khuller, G.K
- Venue
- Tuberculosis
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 83
- Issue
- 6
- Pages
- 373-378
- ISSN
- 1472-9792 (ISSN-L)
- OpenAlex
- W2155750714
- Cited by
- 220
- References
- 21
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 14 · 2021: 10 · 2020: 19 · 2019: 15 · 2018: 11 · 2017: 11 · 2016: 12 · 2015: 9 · 2014: 18 · 2013: 8 · 2012: 16
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Tuberculosis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Keywords
- antitubercular agents, nanoparticle drug delivery, rifampicin, isoniazid, pyrazinamide, oral drug delivery, reduced dosing frequency, Mycobacterium tuberculosis, encapsulation efficiency, murine tuberculosis model
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Administration, Oral, Animals, Antitubercular Agents, Delayed-Action Preparations, Drug Carriers, Drug Compounding, Female, Glycolates, Isoniazid, Liver, Lung, Male, Mycobacterium tuberculosis, Particle Size, Polyglycolic Acid, Pyrazinamide, Rifampin, Spleen, Tuberculosis, Lactic Acid, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
